Company Encyclopedia
View More
name
MiMedx
MDXG.US
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization.
1.946 T
MDXG.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
BiotechnologyIndustry
Industry Ranking32/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE19.44%A
    • Profit Margin10.38%B
    • Gross Margin83.54%A
  • Growth ScoreB
    • Revenue YoY14.77%B
    • Net Profit YoY-50.21%D
    • Total Assets YoY30.79%A
    • Net Assets YoY32.01%A
  • Cash ScoreB
    • Cash Flow Margin963.73%B
    • OCF YoY14.77%B
  • Operating ScoreA
    • Turnover1.4A
  • Debt ScoreB
    • Gearing Ratio25.09%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    MiMedx Group (MDXG) Is Down 8.4% After Strong CAMPAIGN Trial Results for EPIEFFECT Product – What's Changed

    MiMedx Group's stock fell 8.4% despite positive CAMPAIGN trial results for its EPIEFFECT product, which showed superiority in treating diabetic foot ulcers. The trial results enhance MiMedx's clinical profile, but looming Medicare reimbursement changes pose a risk to revenue and margins. The company anticipates $487 million in revenue by 2028, with a fair value estimate of $12.20 per share, suggesting an 80% upside. Investors should consider reimbursement pressures and market contraction risks.

    Simplywall·
    US
    MDXG
    -1.44%
    Simplywall·
    US
    MDXG
    -1.44%

    MiMedx Group (NASDAQ:MDXG) Stock Price Down 5.6% - What's Next?

    MiMedx Group's stock (NASDAQ:MDXG) fell 5.6% during mid-day trading, with a trading volume decline of 32% from the average. Analysts have mixed ratings, with Wall Street Zen upgrading to "strong-buy" and Cantor Fitzgerald raising the price target to $12.00. The company reported a quarterly loss of $0.03 per share with $67.69 million in revenue. Insider trading activity and institutional investor changes were noted, with 79.15% of the stock owned by institutions.

    Market Beat·
    US
    MDXG
    -1.44%
    Market Beat·
    US
    MDXG
    -1.44%

    Northland Securities Sticks to Their Buy Rating for MiMedx Group (MDXG)

    Northland Securities analyst Carl Byrnes maintained a Buy rating for MiMedx Group (MDXG) with a price target of $12.00. Byrnes, who focuses on the Healthcare sector, has an average return of -4.1% and a 36.78% success rate. MiMedx Group also received a Buy rating from TR | OpenAI – 4o’s Dex Genotek, while a Hold rating was reiterated by TR | OpenAI – 4o on October 30.

    Tip Ranks·
    US
    MDXG
    -1.44%
    Tip Ranks·
    US
    MDXG
    -1.44%

    MiMedx Chief Commercial Officer Kimberly Maersk-Moller Reports Sale of Common Shares

    Kimberly Maersk-Moller, Chief Commercial Officer of MiMedx Group Inc., has reported the sale of common shares of the company. The full filing is available through the provided link. This news was generated by Public Technologies and is for informational purposes only, not to be considered as financial or legal advice. MiMedx Group Inc. published the original content via EDGAR on November 10, 2025.

    Reuters·
    US
    MDXG
    -1.44%
    Reuters·
    US
    MDXG
    -1.44%

    MiMedx Group to Join Craig-Hallum Alpha Select and Canaccord MedTech Investor Conferences

    MiMedx Group to Join Craig-Hallum Alpha Select and Canaccord MedTech Investor Conferences

    Reuters·
    US
    MDXG
    -1.44%
    Reuters·
    US
    MDXG
    -1.44%
    © 2025 Longbridge｜Disclaimer